The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 10 April 2006 doi:10.1084/jem.20051496
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 203, Number 4, 843-849
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 2373K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Owyang, A. M.
Right arrow Articles by Artis, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Owyang, A. M.
Right arrow Articles by Artis, D.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

BRIEF DEFINITIVE REPORT

Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract

Alexander M. Owyang2, Colby Zaph1, Emma H. Wilson1, Katherine J. Guild1, Terrill McClanahan2, Hugh R. P. Miller3, Daniel J. Cua2, Michael Goldschmidt1, Christopher A. Hunter1, Robert A. Kastelein2, and David Artis1

1 Department of Pathobiology, University of Pennsylvania, Philadelphia, PA 19104
2 Discovery Research, Schering-Plough Biopharma, Palo Alto, CA 94304
3 Division of Veterinary Clinical Studies, University of Edinburgh, Easter Bush Veterinary Centre, Roslin, Midlothian EH25 9RG, Scotland, UK

CORRESPONDENCE David Artis: dartis{at}vet.upenn.edu

The cytokine interleukin (IL) 25 has been implicated in the initiation of type 2 immunity by driving the expression of type 2 cytokines such as IL-5 and IL-13, although its role in the regulation of immunity and infection-induced inflammation is unknown. Here, we identify a dual function for IL-25: first, in promoting type 2 cytokine-dependent immunity to gastrointestinal helminth infection and, second, in limiting proinflammatory cytokine production and chronic intestinal inflammation. Treatment of genetically susceptible mice with exogenous IL-25 promoted type 2 cytokine responses and immunity to Trichuris. IL-25 was constitutively expressed by CD4+ and CD8+ T cells in the gut of mouse strains that are resistant to Trichuris, and IL-25–deficient mice on a genetically resistant background failed to develop a type 2 immune response or eradicate infection. Furthermore, chronically infected IL-25–/– mice developed severe infection-induced intestinal inflammation associated with heightened expression of interferon-{gamma} and IL-17, identifying a role for IL-25 in limiting pathologic inflammation at mucosal sites. Therefore, IL-25 is not only a critical mediator of type 2 immunity, but is also required for the regulation of inflammation in the gastrointestinal tract.


A.M. Owyang and C. Zaph contributed equally to this work.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article

Helper T cell differentiation enters a new era: Le Roi est mort; vive le Roi!
Cristina M. Tato, Arian Laurence, and John J. O'Shea
J. Exp. Med. 2006 203: 809-812. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS